Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 84 | 0.82 |
| pathways Reactome | 29 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 12116
Sealed predictions
- GNB5 in dopamine neurons, braak+0.39 (p 0.306) → -0.52 (p 0.152)receipt 12123
Swarm cases
receipt 12123: GNB5 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.258, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.246, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.225, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.20, sign flips 0; without severely affected donors -0.28 (p 0.258, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.66 (p 0.0031, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GNB5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GNB5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.02 p 0.929 (needs p < 1.8e-4)
Receipts
loading the receipts